← boardnext 2026-12-01next 2028-11
ALMS
Alumis Incdistress 4/10 · elevated risk$28.03-3%today-7% from 52w high
Immunology / Inflammation 2Nephrology 1
Lead: moderate-to-severe plaque psoriasis · target TYK2 · est. market ~$30B (approx, global)
Revenue
pre-revenue
Liquidity
$283M
Runway
0.8 yrs
Shares 1y
—
Price & events
+6.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.7%
1D
+2.9%
1W
+14.4%
1M
+7.8%
3M
+14.3%
6M
+629.9%
1Y
+122.5%
2Y
—
5Y
+110.8%
All
Overview
- Volume
- 139.69K
- 52 Week Range
- $3.31 – $30.30
- Float Shares
- 85.84M
- Short %
- 19.95%
- % Held by Insiders
- 0.62%
- % Held by Institutions
- 99.91%
- RVOL
- 0.09x
- Beta
- -0.71
Pipeline stages · 3 programs
envudeucitinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Open-Label Envudeucitinib, Blinded Envudeucitinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ESK-001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 7 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-01 Estimated 50% readout ~2027-01-15 | Phase 2 | envudeucitinib | Plaque Psoriasis | — | active not recruiting |
| 2028-11 Estimated 50% readout ~2029-01-15 | Phase 3 | Open-Label Envudeucitinib, Blinded Envudeucitinib | Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis | — | active not recruiting |
| 2026-07-01 | Phase 2 | Envudeucitinib | SLE | 408 | active not recruiting |
| 2026-03-24 | Phase 1 | envudeucitinib | Hepatic Impairment | 32 | completed |
| 2025-09-23 | Phase 3 | Envudeucitinib, Apremilast | Plaque Psoriasis | 862 | completed |
Show all 7 trials · 2 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-09-19 | Phase 3 | Envudeucitinib, Apremilast | Plaque Psoriasis | 912 | completed |
| 2025-08-01 | Phase 1 | ESK-001 | Renal Impairment | 16 | completed |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 16
- 1H 2027Guided 55%trial initiationsecondaryPhase 2A-005 · Initiation of Phase 2 biomarker trialSEC 8-K
- 2026Guided 40%readoutPhase 1Undisclosed · Phase 1 data for next programSEC 8-K
- 4Q 2026Guided 70%regulatory submissionFiled (NDA/BLA)envudeucitinib · NDA submission for psoriasisSEC 8-K
- 2H 2026Guided 55%readoutPhase 3envudeucitinib · Additional data from Phase 3 psoriasis programSEC 8-K
- Q3 2026Guided 70%readoutPhase 2Envudeucitinib · Phase 2b topline data for envudeucitinib in SLESEC 8-K
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- second half of 2026regulatory submissionFiled (NDA/BLA)envudeucitinib · Planned FDA New Drug Application submission.SEC 8-K
- 1H 2026trial initiationsecondaryPhase 2A-005 · Initiate Phase 2 trial of A-005 in multiple sclerosisSEC 8-K
- early Q1 2026readoutPhase 3Envudeucitinib · Phase 3 topline data for envudeucitinib in psoriasisSEC 8-K
- first quarter of 2026readoutPhase 3ESK-001 · Topline data from Phase 3 ONWARD program expectedSEC 8-K
- 2025-05-21partnershipAlumis completed merger with ACELYRIN, making ACELYRIN a wholly owned subsidiary.SEC 8-K
- 2025-04-20partnershipAmendment to merger agreement with ACELYRIN, exchange ratio set at 0.4814 shares of Alumis common stock per ACELYRIN share.SEC 8-K
- 2025-03-25partnershipESK-001 · Exclusive license to Kaken for dermatology in Japan with options for rheumatology and GI; $40M upfront and near-term payments, up to $140M milestones plus royalties.SEC 8-K
- March 8, 2025conferencedata presentationsecondaryPhase 2ESK-001 · Late-breaking 52-week OLE data presented at AAD Annual MeetingSEC 8-K
- 2025-03-04partnershipAlumis and ACELYRIN reaffirm commitment to all-stock merger.SEC 8-K
- 2025-02-06partnershipAlumis and ACELYRIN entered into an Agreement and Plan of MergerSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $40 (+43% upside) · 10 analysts
- 2026-05-19Chardan CapitalBuy
- 2026-05-15Wells FargoOverweight
- 2026-05-15GuggenheimBuy
- 2026-05-15HC Wainwright & Co.Buy → Neutral
- 2026-03-30OppenheimerOutperform
- 2026-03-30Chardan CapitalBuy
Competitors — TYK2
- none identified
Recent news
- 2026-07-15(ALMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
- 2026-07-10Alumis Inc. (ALMS) Receives a Rating Update from a Top Analyst - The Globe and Mail
- 2026-07-09Stifel Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $44 - Moomoo
- 2026-07-09Stifel reiterates Alumis stock Buy rating ahead of lupus data By Investing.com - Investing.com South Africa
- 2026-07-09Stifel reiterates Alumis stock Buy rating ahead of lupus data By Investing.com - Investing.com Canada
- 2026-07-09Stifel reiterates Alumis stock Buy rating ahead of lupus data - Investing.com
- 2026-07-08Form 4 Alumis Inc For: 8 July By Investing.com - Investing.com Nigeria
- 2026-07-08Alumis Inc stock hits all-time high at 30.67 USD By Investing.com - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.